LEBANON – On Tuesday federal agencies have called for a temporary pause to the administration of the Johnson & Johnson (J&J) Janssen COVID-19 vaccine while investigating reports of six individuals experiencing blood clots within three weeks of receiving the injection. Section Chief of Hematology Medicine at Dartmouth-Hitchcock Medical Center, Christopher Lowrey, MD, addresses concerns in a video update.

“While Dartmouth-Hitchcock Health (D-HH) is following national guidance and temporarily suspending use of the Johnson & Johnson (J&J) COVID-19 vaccine, it’s important to remember that of the approximately 37,000 J&J vaccines that have been given in NH to date, there have been no reported cases of adverse events in the state,” said Lowrey. “I want to reassure our patients, staff, and community that D-HH continues to stand by the importance of the COVID-19 vaccines and applaud the federal agencies for taking the necessary steps to evaluate and review the data involved in the six reported US cases.”

Visit the D-HH website for the most up-to-date information.

Newsletter